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Noninferiority trial investigating the efficacy of a nonantibiotic 
intramammary therapy in the treatment of mild- to- moderate 
clinical mastitis in dairy cows with longer lasting udder diseases
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1  | INTRODUCTION






cases,	 farmers	decided	to	use	antibiotic	 treatment.	Other	 investiga-
tions	conducted	in	51	large	dairy	herds	in	Wisconsin,	USA,	reported	





sure	 prudent	 use	 of	 antibiotics	 (Mansion-	de	Vries,	 Hoedemaker,	 &	
Krömker,	2015;	Ruegg,	2010)	because	it	 is	 impossible	to	prevent	all	
CM	cases.	Trevisi	et	al.	 (2014)	mentioned	 that	antibiotic	 treatments	
for	chronic	disease	cases	do	not	lead	to	increased	animal	health	and	
are	not	 reasonable	with	 regard	 to	 cost/benefit	 analysis.	The	aim	of	
antibiotic	therapy	must	be	considered	to	determine	the	benefit	of	an-











2009;	 Pinzón-	Sánchez	&	 Ruegg,	 2011;	 Sol,	 Sampimon,	 Barkema,	&	












symptomatically	 to	 avoid	 useless	 application	 of	 antibiotics	 (Degen,	



























was	 to	 evaluate	 noninferiority	 of	 the	 test	 products	 against	 the	 ref-
erence	product	for	treatment	of	mild-	to-	moderate	CM	in	cows	with	
longer	lasting	udder	diseases.





















Based	 on	 investigations	 of	 Schukken	 et	al.	 (2011),	 the	 margin	 of	
noninferiority	(∆)	was	determined	as	0.15	for	this	study.	Also,	other	
investigators	 recommended	 and	 applied	 this	 value	 for	 noninferi-
ority	margin	 in	CM	 studies	 (Deluyker,	Chester,	&	 van	Oye,	 1999;	









reference	and	test	 treatment,	 then	37	CM	cases	per	group	are	 re-
quired	so	as	to	be	90%	sure	that	the	upper	limit	of	a	one-	sided	95%	

















Every	 cow	must	 be	 registered	with	 a	 unique	 ear	 tag	 to	 clearly	
identify	every	animal,	as	stipulated	in	Germany.	Only	cows	that	have	
had	at	least	three	consecutively	high	CSCC	(>	400,000	somatic	cells/




igible	 for	 inclusion.	 Suitable	 cows	 showed	 a	 period	 of	 normal	milk	
secretion	without	signs	of	 inflammation	on	the	udder	quarters	until	
start	 of	 CM.	The	 subsequent	 clinical	 score	was	 used	 to	 character-
ize	and	determine	CM	at	occurrence.	A	quarter	was	classified	as	af-
















treatment	as	usual	on	 the	 farm	according	 to	 label	of	 the	 respective	
product;	 group	2)	ABMV,	antibiotic	 treatment	as	usual	on	 the	 farm	
according	 to	 label	 of	 the	 respective	 product	 combined	 with	 Masti	
Veyxym®	 (Veyx-	Pharma	GmbH,	Schwarzenborn,	Germany)	compris-
ing	 three	 treatments	 of	 10-	g	 disposable	 syringe	 containing	 120	mg	
α-	tocopherol	 acetate,	 58.83	mg	 retinol	 palmitate,	 2,400	 FIP-	U	 chy-











structured	 in	 the	 following	way,	 the	 first	 affected	 cow	meeting	 the	
inclusion	criteria	was	assigned	to	the	treatment	group	AB,	the	second	




















of	 the	 respective	 product.	 In	 the	 combined	 therapy	 group	 (ABMV),	
first	 the	 antibiotic	 and	 immediately	 afterwards	 the	Masti	 Veyxym® 
were	 injected.	At	 every	milking	 period,	 the	 clinical	 score	 of	 the	 af-
fected	quarter	was	assessed	by	the	milkers	until	7	days	after	the	end	
of	 treatment.	 When	 clinical	 signs	 deteriorated,	 the	 farmer	 was	 al-
lowed	to	treat	the	cow	with	an	additional	or	different	treatment	and	
the	case	was	documented	as	treatment	failure.	CM	cases	where	the	
14  |     ZIESCH Et al.
clinical	signs	disappeared	until	day	7	after	the	end	of	treatment	and	
without	classification	as	treatment	failure	were	assessed	as	clinically	
cured.	 These	 cured	 quarters	 were	 observed	 from	 day	 8	 to	 day	 60	









study.	 Commonly	 used	 cow-	level	 data	 including	 lactation	 number,	
affected	quarter	 location,	milk	yield,	CSCC	of	the	three	most	recent	












was	 used	 in	 test	 tubes	 (GVA	 [German	 Veterinary	 Association],	
2009).	The	samples	were	sent	to	the	microbiological	 laboratory	at	
the	University	of	Applied	Sciences	and	Arts	Hannover	 (Germany).	
Microbiological	 examinations	were	 performed	 in	 accordance	with	
the	guidelines	of	the	German	Veterinary	Association	(GVA	[German	
Veterinary	 Association],	 2009),	 which	 are	 based	 on	 National	
Mastitis	 Council	 recommendations	 (NMC	 (National	 Mastitis	
Council),	 1999);	 10	μl	 of	 each	milk	 sample	was	plated	on	 a	quad-
rant	 of	 an	 aesculin	 blood	 agar	 plate	 (Oxoid,	 Germany)	 and	 incu-





formed	 to	 determine	 the	 growing	micro-	organisms.	 The	 clumping	
factor	test	(DiaMondiaL	Staph	Plus	Kit,	Sekisui	Virotech,	Germany)	
instead	of	the	coagulase	test	was	used	to	differentiate	presumptive	
Staphylococcus	 (S.)	 aureus	 from	 coagulase-	negative	 staphylococci	
(CNS).	Different	aesculin-	negative	streptococci	were	distinguished	
by	the	serological	tests	for	Lancefield	Group	B	(Streptococcus (Sc.) 
agalactiae),	 C	 (Sc. dysgalactiae)	 and	 G	 (DiaMondiaL	 Streptococcal	
Extraction	 Kit	 Sekisui	 Virotech,	 Germany).	 To	 differentiate	 be-
tween	Sc. uberis and Enterococcus	spp.,	the	modified	Rambach	agar	
according	 to	Watts,	 Salmon,	 and	Yancey	 (1993)	was	 used.	Gram-	
positive,	 beta-	haemolytic	 and	 catalase-	negative	 irregular	 rods	
with	 a	V-	or	Y-	shaped	 configuration	were	 identified	 as	Trueperella 
(T.) pyogenes.	 Coryneform	 bacteria	 form	 small	 colonies	 on	 aes-
culin	 blood	 agar.	 They	 are	 gram-	positive	 and	 catalase-	positive.	
Both	T. pyogenes	 and	 coryneform	 bacteria	 are	 asporogen.	Bacillus 
spp.	 form	 large	 colonies	 on	 aesculin	 blood	 agar.	Bacillus	 spp.	 are	
gram-	positive,	 catalase-	positive	 rods	 and	 can	 form	 endospores.	
Coliform	 bacteria	 are	 gram-	negative,	 catalase-	negative	 and	 cy-
tochrome	 oxidase-	negative	 (Bactident	 oxidase,	 Merck,	 Germany)	
rod-	shaped	 bacteria,	 which	 can	 metabolize	 glucose	 fermenta-
tively	 (OF	 basal	 medium	with	 addition	 of	 D	 (+)-	glucose	monohy-
drate,	 Merck,	 Germany).	 On	 Chromocult	 Coliform	 Agar	 (Merck,	
Germany),	 Escherichia	 (E.)	 coli	 forms	 blue	 colonies	 under	 aerobic	













more	 than	 two	pathogens	were	 identified,	 except	 in	 cases	where	
also	 S. aureus,	 Sc. agalactiae,	 Sc. dysgalactiae and T. pyogenes were 
cultured.	Then,	only	the	growth	of	these	pathogens	was	recorded,	
and	the	cases	were	classified	as	contaminated	if	the	samples	con-
tained	more	 than	 two	of	 these	pathogens.	 The	Somascope	Smart	
(Delta	 Instruments,	 The	 Netherlands)	 was	 used	 to	 determine	 the	
quarter	SCC	(QSCC)	by	flow	cytometry.
2.8 | Outcome variables













recurrent	 quarters	when	 one	 or	more	 CM	 cases	were	 detected.	A	
quarter	showed	no	R60	if	it	was	free	of	CM	within	the	observed	time	
frame.
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Bacteriological	 cure	 was	 defined	 as	 the	 absence	 of	 the	
pathogen-	cultured	 pretreatment	 in	 both	 post-	treatment	 samples	
at	days	14	and	21.	If	a	bacterial	species	other	than	the	pathogen-	
cultured	pretreatment	was	isolated	in	the	post-	treatment	samples,	
the	 case	was	 still	 defined	 as	 bacteriologically	 cured.	 In	 case	 one	
post-	treatment	 sample	 was	 contaminated,	 the	 outcome	 of	 the	
other	post-	treatment	sample	was	used	to	determine	the	BC.	If	two	
pathogens	were	isolated	in	the	pretreatment	sample,	the	case	was	






QSCC	 cure	was	 defined	 as	 a	QSCC	 being	 <200,000	 cells/ml	 in	










The	 data	 were	 collected	 and	 analysed	 using	 Excel,	 Office	 2010	
(Microsoft	 Corporation)	 and	 SPSS	 (IBM	 SPSS	 23.0.0.0,	 Armonk,	






number,	 DIM	 and	 pathogen-	cultured	 pretreatment	 as	 important	
covariates.	As	clustering	was	present	in	the	design	(i.e.,	gland	within	
cow	and	cow	within	herd),	the	analysis	was	corrected	using	random	










grouped	 into	 Enterobacteriaceae,	 streptococci,	 staphylococci,	 other	
pathogens,	contaminated	samples	and	no	growth.
For	CC,	no	R60	and	BC,	 the	model	was	used	 to	calculate	 least-	
square	means	 of	 the	various	 treatment	 groups.	Thereby,	 the	 differ-
ences	 between	 treatments	 were	 estimated.	 Confidence	 intervals	








and	 800	 lactating	 Holstein-	Friesian	 dairy	 cows.	 The	 milk	 produc-
tion	ranged	from	8,000	and	9,700	kg/cow/year	with	bulk	milk	SCC	













ml;	maximum	9,694,000	 cells/ml)	 and	of	milk	yield	 last	DHI	before	
CM	occurrence	30.15	kg	(minimum	10.3	kg;	maximum	58.4	kg).	In	89	
cases	 the	 front	quarters	and	 in	85	cases	 the	 rear	quarters	 suffered	




































3.2 | Homogeneity of treatment groups
No	 significant	 differences	 between	 treatment	 groups	 in	 DIM	 and	
pathogen-	cultured	 pretreatment	were	 found	 (p > .2).	 Treatment	was	










means	of	63.8%	 for	 the	AB	group,	62.2%	 for	 the	ABMV	group	and	
58.3%	 for	 the	MV	group.	However,	no	 significant	differences	 in	CC	
of	the	reference	treatment	AB	to	the	test	treatment	MV	(p = .61)	and	
to	 the	 test	 treatment	ABMV	 (p = .875)	were	 found	 (Table	3).	 Cows	






3.4 | No recurrence 60 days
Only	quarters	with	clinically	cured	cases	of	cows,	which	were	still	in	
milk	60	days	after	 the	end	of	 treatment,	were	 included	 in	this	anal-
ysis	 (Pinzón-	Sánchez	 &	 Ruegg,	 2011).	 Of	 the	 109	 clinically	 cured	
quarters,	23	cases	were	excluded	because	the	cow	had	been	dried-	














Furthermore,	 animals	 contracting	 CM	 over	 200	 DIM	 had	 a	 signifi-
cantly	higher	 likelihood	of	no	R60	compared	 to	cows	suffering	 from	
CM	within	0–100	DIM	(p = .009)	and	cows	affected	with	CM	within	
101–200	DIM	(p = .043).	CM	cases	caused	by	staphylococci	showed	

















Escherichia coli 3 1.8
Streptococci 35
Streptococcus uberis 24 14.2
Streptococcus dysgalactiae 8 4.7
Other	streptococci 3 1.8
Staphylococci 36
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missing	post-	treatment	samples	(eight	cases).	The	overall	BC	rate	was	
34.9%	 (45/129).	The	probability	of	BC	 in	 the	AB	group	was	37.2%	
(16/43),	 in	 the	 ABMV	 group	 39.1%	 (18/46)	 and	 in	 the	 MV	 group	
27.5%	(11/40),	respectively.











3.6 | Quarter somatic cell count cure
Overall	 twelve	 CM	 cases	 were	 excluded	 from	 this	 analysis	 due	 to	
missing	post-	treatment	samples	(seven	cases)	or	the	cow	was	dried-	
off	 (three	 cases)	 or	 slaughtered	 (one	 case)	 or	 suffered	 from	 a	 teat	
injury	(one	case)	before	at	least	the	first	post-	treatment	sample	was	
collected.	The	pretreatment	CSCC	and	 the	course	of	QSCC	 for	 the	
examined	treatment	groups	are	shown	in	Table	6.	The	overall	QSCC	


















2013;	 Swinkels	 et	al.,	 2014).	 The	 small	 variations	 in	 CC	 rates	were	
Variable
Coefficient
OR 95% CI p- valueaX SE
Intercept −0.399 0.594 0.671 0.206–2.189 .504
Treatment
MV 0.231 0.451 1.260 0.513–3.093 .610
ABMV 0.069 0.440 1.072 0.446–2.574 .875
AB	(reference) 0
Lactation	number	of	the	cow	at	the	day	of	clinical	mastitis	occurrence
1 0.256 0.448 1.291 0.529–3.151 .570
2 0.182 0.404 1.199 0.537–2.680 .654
>2	(reference) 0
Days	in	milk	at	the	day	of	clinical	mastitis	occurrence
0–100 −0.433 0.460 0.649 0.260–1.620 .349
101–200 −0.959 0.414 0.383 0.168–0.873 .023
>200	(reference) 0
Pathogen	cultured	from	the	pretreatment	milk	sample
Enterobacteriaceae 0.813 0.917 2.254 0.363–13.984 .378
Streptococci 0.714 0.559 2.043 0.672–6.209 .205
Staphylococci 0.082 0.580 1.086 0.342–3.441 .888
Other	pathogens −0.178 0.540 0.837 0.286–2.454 .743
Contaminated	
sample
























this	 range	 is	 to	 increase	 sample	 size.	The	noninferiority	margin	 also	
influences	 the	 outcome	 and	was	 chosen	 according	 to	 previous	 CM	




et	al.	 (2013).	 The	 nonantibiotic	 treatment	 showed	 a	 numerically	 al-
most	identical	CC	rate	and	no	significant	differences	to	the	reference	
treatment;	noninferiority	was	inconclusive	due	to	the	lack	of	power.
The	 other	 primary	 outcome	 variable	was	 no	 R60.	 The	 probabil-
ity	 of	 achieving	 no	 CM	 recurrence	 within	 60	days	 after	 the	 end	 of	
























Bacteriological	 cure	was	 investigated	as	 secondary	outcome	be-
cause	a	poor	probability	of	BC	for	included	CM	cases	was	expected.	
This	 study	 resulted	 in	 much	 lower	 BC	 rates	 for	 CM	 cases	 treated	
with	 antibiotics	 (AB	 group	37.2%;	ABMV	group	39.1%)	 in	 compari-
son	with	other	studies,	which	showed	a	BC	rate	of	approximately	70%	
(Schukken	et	al.,	2013;	Swinkels	et	al.,	2014).	The	high	differences	in	
BC	 rates	 support	 the	selection	criteria	used	 in	 this	 study	 to	choose	
cows	 suffering	 from	CM	with	 a	 low	 likelihood	of	BC.	Nevertheless,	
a	 tendency	 for	 the	 efficacy	 of	 antibiotic	 treatment	 against	 masti-
tis	pathogens	was	shown.	The	probability	of	BC	in	the	nonantibiotic	
treatment	 group	 (MV)	 was	 27.5%	 and	 therefore	 numerically	 lower	















with	 antibiotics.	 Furthermore,	 advantageous	 properties	 of	 Masti	
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Variable
Coefficient
OR 95% CI p- valueaX SE
Intercept 1.759 1.323 5.805 0.405–83.149 .190
Treatment
MV −0.475 0.804 0.622 0.125–3.086 .556
ABMV 1.306 0.753 3.693 0.822–16.590 .087
AB	(reference) 0
Lactation	number	of	the	cow	at	the	day	of	clinical	mastitis	occurrence
1 1.843 0.809 6.315 1.260–31.665 .026
2 2.137 0.791 8.476 1.752–41.006 .009
>2	(reference) 0
Days	in	milk	at	the	day	of	clinical	mastitis	occurrence
0–100 −2.815 1.050 0.060 0.007–0.486 .009
101–200 −1.939 0.941 0.144 0.022–0.940 .043
>200	(reference) 0
Pathogen	cultured	from	the	pretreatment	milk	sample
Enterobacteriaceae −1.002 1.744 0.367 0.011–11.887 .567
Streptococci 0.628 0.980 1.873 0.265–13.221 .524
Staphylococci −2.028 1.008 0.132 0.018–0.982 .048
Other	pathogens −0.510 0.884 0.601 0.103–3.501 .566
Contaminated	
sample




















OR 95% CI p- valueaX SE
Intercept 0.563 0.544 1.756 0.598–5.153 .302
Treatment
MV 0.808 0.559 2.243 0.741–6.786 .151
ABMV 0.303 0.531 1.353 0.473–3.871 .570
AB	(reference) 0
Lactation	number	of	the	cow	at	the	day	of	clinical	mastitis	occurrence
1 −0.284 0.539 0.753 0.259–2.189 .599
2 0.274 0.464 1.315 0.525–3.297 .556
>2	(reference) 0
Days	in	milk	at	the	day	of	clinical	mastitis	occurrence
0–100 0.186 0.604 1.204 0.364–3.985 .759
101–200 −1.577 0.488 0.207 0.079–0.543 .002
>200	(reference) 0
Pathogen	cultured	from	the	pretreatment	milk	sample
Enterobacteriaceae 0.103 0.887 1.109 0.191–6.424 0.908
Streptococci 0.766 0.510 2.151 0.784–5.905 0.136
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farms.	That	 implies	 no	 information	 about	 the	 causative	 pathogen	 at	
the	time	of	CM	treatment.	Therefore,	and	because	power	calculations	




















combined	Masti	 Veyxym®	 with	 antibiotics	 (ABMV)	 in	 comparison	
with	 antibiotic	 treatment	 (AB;	 reference)	 of	mild-	to-	moderate	CM	
in	cows	with	longer	lasting	udder	diseases.	The	two	test	treatments	
showed	no	significant	differences	 to	 the	 reference	 treatment	with	
respect	 to	 the	 outcome	 variables	 such	 as	 clinical	 cure,	 no	CM	 re-
currence	 within	 60	days	 after	 the	 end	 of	 therapy,	 bacteriological	
cure	 and	quarter	 somatic	 cell	 count	 cure.	 The	 solely	 nonantibiotic	






ment	 of	 mild-	to-	moderate	 CM	 in	 cows	 with	 longer	 lasting	 udder	
diseases	may	 constitute	 an	 alternative	 therapy	 to	 reduce	 antibiot-
ics.	However,	 to	 give	 a	 reliable	 noninferiority	 evaluation,	 a	 higher	
sample	size	is	needed.	The	selection	criteria	of	cows	have	to	be	re-





(Schwarzenborn,	 Germany)	 for	 supporting	 the	 study	 and	 providing	
pharmaceuticals.
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